AstraZeneca gets a boost from durvalumab PhIII chatter as pipeline wear and tear starts to show
AstraZeneca shares have been surging in the wake of the Brexit breakup vote, and some boosters of the UK pharma giant are interpreting the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
